Search

High Purity & QualityEvery batch reaches ≥98% purity, verified by HPLC and mass spectrometry before release.Scalable ProductionFrom R&D samples to bulk commercial supply — consistent quality at any order volume.Fast Global DeliveryIn-stock peptides ship within 1–3 business days. Cus

Radiptide operates a GMP-aligned synthesis and testing facility in Guangzhou. From raw material intake through SPPS synthesis, multi-column HPLC purification, lyophilization and nitrogen-sealed packaging, every step is documented and traceable.We support catalog cosmetic peptides and custom se

We understand that raw material quality defines your product reputation. That is why every Radiptide batch goes through rigorous release testing before it leaves our facility.GMP-compliant manufacturing with standardized production workflowsHPLC purity verification on every batchMass spectrome

The FDA approved rusfertide (MIMRYLO) on August 28, 2026 for polycythemia vera patients needing frequent phlebotomy—marking the first hepcidin-mimetic peptide therapy in the United States.

PVX108 received FDA Fast Track designation in August 2026 as a synthetic T-cell epitope peptide therapy for peanut allergy—one of the first allergen immunotherapy programs built entirely on short peptides rather than whole extracts.

ENDO 2026 in Chicago drew more than 8,000 attendees as GLP-1, dual-agonist, and triple-agonist peptides filled plenary slots, poster halls, and late-breaking abstract sessions.

Peptide suppliers face new scorecard metrics on solvent recovery and waste intensity in 2026.

Cosmetic buyers tighten peptide release criteria; data integrity rises on 2026 audit agendas.

Technical review of peptide degradation in multi-active formulas and proven mitigation steps.

An analysis of GHK-Cu demand, tightening COA specs, and formulation best practices in 2025.